Vanguard Group
THRX

Vanguard Group’s Theseus Pharmaceuticals, Inc. Common Stock THRX Stock Holding History

Vanguard Group’s Portfolio THRX Stock Details THRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-795,549
Closed -$3.22M – 4526
2023
Q4 		$3.22M Buy
795,549
+6,429
+0.8% +$19.6K ﹤0.01% 3439
2023
Q3 		$2.12M Buy
789,120
+57,695
+8% +$226K ﹤0.01% 3558
2023
Q2 		$6.82M Buy
731,425
+30,464
+4% +$300K ﹤0.01% 3159
2023
Q1 		$6.22M Buy
700,961
+62,489
+10% +$613K ﹤0.01% 3203
2022
Q4 		$3.18M Buy
638,472
+12,529
+2% +$73.4K ﹤0.01% 3493
2022
Q3 		$3.63M Sell
625,943
-3,371
-0.5% -$23.8K ﹤0.01% 3490
2022
Q2 		$3.48M Buy
629,314
+142,952
+29% +$1.18M ﹤0.01% 3552
2022
Q1 		$5.61M Sell
486,362
-396
-0.1% -$4.23K ﹤0.01% 3474
2021
Q4 		$6.17M Buy
+486,758
New +$7.35M ﹤0.01% 3494

Vanguard Group's THRX Position: Q1 2024 in Review

Vanguard Group sold out of Theseus Pharmaceuticals, Inc. Common Stock (THRX) in Q1 2024, closing a stake of 795,549 shares — an estimated $3.22M sold.

Vanguard Group first reported a position in THRX in Q4 2021 and held it in 9 quarters. The position peaked at $6.82M in Q2 2023. 1 fund tracked by Wall St. Rank holds THRX as of Q1 2024.

  • Vanguard Group reported no remaining Theseus Pharmaceuticals, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
  • Vanguard Group sold 795,549 Theseus Pharmaceuticals, Inc. Common Stock shares in Q1 2024, an estimated $3.22M.
  • Vanguard Group first reported a position in Theseus Pharmaceuticals, Inc. Common Stock in Q4 2021 and held it in 9 quarters.
  • Vanguard Group's Theseus Pharmaceuticals, Inc. Common Stock position peaked at $6.82M in Q2 2023.
  • 1 fund tracked by Wall St. Rank held Theseus Pharmaceuticals, Inc. Common Stock as of Q1 2024.

Based on Vanguard Group's 13F filing for Q1 2024, filed 10 May 2024.